Pathophysiologic mechanisms of acute graft-vs.-host disease
- PMID: 10595812
- DOI: 10.1016/s1083-8791(99)70011-x
Pathophysiologic mechanisms of acute graft-vs.-host disease
Abstract
Graft-vs.-host disease (GVHD) remains the major toxicity of allogeneic bone marrow transplantation. Mechanistic studies in experimental animal models provide a better understanding of the complex relationships and cascade of events mediated by cellular and inflammatory factors. Also, advances in basic immunology have cleared the way for a more precise view of allogeneic reactions between donor and host. In addition, the use of mutant mice lacking critical cytolytic proteins has helped map out the molecular pathways by which GVHD targets organ damage. In this article, these mechanisms are reviewed and synthesized into a coherent conceptual framework, providing a state-of-the-art summary of the pathophysiology of acute GVHD.
Similar articles
-
The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease.J Endotoxin Res. 2002;8(6):441-8. doi: 10.1179/096805102125001046. J Endotoxin Res. 2002. PMID: 12697087 Review.
-
Cellular and cytokine effectors of acute graft versus host disease.Int J Hematol. 2002 Aug;76 Suppl 1:195-8. doi: 10.1007/BF03165244. Int J Hematol. 2002. PMID: 12430853
-
Acute graft versus host disease: pathophysiology, risk factors, and prevention strategies.Clin Adv Hematol Oncol. 2005 May;3(5):415-9, 428. Clin Adv Hematol Oncol. 2005. PMID: 16167015 Review.
-
Acute graft-vs-host disease: pathobiology and management.Exp Hematol. 2001 Mar;29(3):259-77. doi: 10.1016/s0301-472x(00)00677-9. Exp Hematol. 2001. PMID: 11274753 Review.
-
Host-Derived CD70 Suppresses Murine Graft-versus-Host Disease by Limiting Donor T Cell Expansion and Effector Function.J Immunol. 2017 Jul 1;199(1):336-347. doi: 10.4049/jimmunol.1502181. Epub 2017 May 26. J Immunol. 2017. PMID: 28550198 Free PMC article.
Cited by
-
Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease.J Clin Invest. 2002 May;109(10):1335-44. doi: 10.1172/JCI14989. J Clin Invest. 2002. PMID: 12021249 Free PMC article.
-
Beta2 integrins separate graft-versus-host disease and graft-versus-leukemia effects.Blood. 2008 Jan 15;111(2):954-62. doi: 10.1182/blood-2007-05-089573. Epub 2007 Oct 10. Blood. 2008. PMID: 17928532 Free PMC article.
-
Murine models of chronic graft-versus-host disease: insights and unresolved issues.Biol Blood Marrow Transplant. 2008 Apr;14(4):365-78. doi: 10.1016/j.bbmt.2007.12.002. Epub 2008 Feb 13. Biol Blood Marrow Transplant. 2008. PMID: 18342778 Free PMC article. Review.
-
Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity.J Immunol. 2011 Nov 15;187(10):5130-40. doi: 10.4049/jimmunol.1101334. Epub 2011 Oct 17. J Immunol. 2011. PMID: 22013117 Free PMC article.
-
PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice.J Clin Invest. 2009 Dec;119(12):3774-86. doi: 10.1172/JCI39692. Epub 2009 Nov 9. J Clin Invest. 2009. PMID: 19907075 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources